Home › Multiple Myeloma › Michigan
Multiple Myeloma clinical trials in Michigan
27 studies for Multiple Myeloma are looking for participants at sites in Michigan.
Cities in Michigan
- Detroit19 studies
- Ann Arbor13 studies
- Grand Rapids8 studies
- Lansing4 studies
- Flint3 studies
- Waterford3 studies
- Livonia3 studies
- Saginaw3 studies
- Warren3 studies
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05137054A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07393282A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Barbara Ann Karmanos Cancer Institute, Detroit
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
- Cancer And Hematology Centers of Western Michigan PC, Grand Rapids
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Michigan Rogel Cancer Center, Ann Arbor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Michigan Health System, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT04634552Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- University of Michigan, Ann Arbor
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07280013AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06106945A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06953960A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- University of Michigan, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Detroit
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT07735637A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- START Midwest /ID# 279035, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT07409246A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Henry Ford Health System, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06980480AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Ann Arbor
- Research Site, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT05850234A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Henry Ford Health Saint John Hospital, Detroit
- Genesys Hurley Cancer Institute, Flint
- and 7 more
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- and 36 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06292780Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06057402Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- KCI at McLaren Greater Lansing, Lansing
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT06107738Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Joseph Mercy Hospital, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Saint Joseph Mercy Brighton, Brighton
- and 51 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Ann Arbor
- GSK Investigational Site, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- Karmanos Cancer Institute, Detroit
Recruiting
Ages 18 and older · All sexes · Updated Aug 26, 2025 · NCT06908629From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.